Baillie Gifford & CO Vertex Pharmaceuticals Inc Transaction History
Baillie Gifford & CO
- $127 Billion
- Q4 2024
A detailed history of Baillie Gifford & CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baillie Gifford & CO holds 149,838 shares of VRTX stock, worth $69.3 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
149,838
Previous 140,580
6.59%
Holding current value
$69.3 Million
Previous $65.4 Million
7.71%
% of portfolio
0.05%
Previous 0.05%
Shares
12 transactions
Others Institutions Holding VRTX
# of Institutions
1,732Shares Held
227MCall Options Held
1.65MPut Options Held
1.32M-
Capital World Investors Los Angeles, CA28.3MShares$13.1 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$10.8 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.86 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.47 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$4.82 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $119B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...